Serum IGF1, IGF2 and IGFBP3 and risk of advanced colorectal adenoma

International Journal of Cancer

Volumn 131, Issue 2, 2012, Pages

  Gao, Ying ^a   Katki, Hormuzd ^a   Graubard, Barry ^a   Pollak, Michael ^b   Martin, Michael ^c   Tao, Yuzhen ^b   Schoen, Robert E ^d   Church, Timothy ^e,f   Hayes, Richard B ^g   Greene, Mark H ^a   Berndt, Sonja I ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b MCGILL UNIVERSITY   (Canada)

^c SLIGO UNIVERSITY HOSPITAL   (Ireland)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF MINNESOTA   (United States)

^f HENRY FORD HOSPITAL   (United States)

^g NEW YORK UNIVERSITY   (United States)

Author keywords

colorectal adenoma; insulin like growth factor

Indexed keywords

SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BODY MASS; CANCER RISK; CANCER SCREENING; CARCINOGENESIS; CASE CONTROL STUDY; COLORECTAL ADENOMA; CONTROLLED STUDY; EDUCATIONAL STATUS; ENZYME LINKED IMMUNOSORBENT ASSAY; ETHNICITY; FAMILY HISTORY; FEMALE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; RISK ASSESSMENT; SIGMOIDOSCOPY; SMOKING;

ADENOMA; AGED; CASE-CONTROL STUDIES; COLORECTAL NEOPLASMS; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; INSULIN-LIKE GROWTH FACTOR II; MALE; MIDDLE AGED; RISK; TUMOR MARKERS, BIOLOGICAL;

EID: 84861635009     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.26438     Document Type: Article

References (46)

1. Pollak M,. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 2008; 8: 915-28.
2. Butler AA, Le Roith D,. Control of growth by the somatropic axis: growth hormone and the insulin-like growth factors have related and independent roles. Annu Rev Physiol 2001; 63: 141-64.
3. Rajaram S, Baylink DJ, Mohan S,. Insulin-like growth factor-binding proteins in serum and other biological fluids: regulation and functions. Endocr Rev 1997; 18: 801-31.
4. Campana WM, Darin SJ, O'Brien JS,. Phosphatidylinositol 3-kinase and Akt protein kinase mediate IGF-I- and prosaptide-induced survival in Schwann cells. J Neurosci Res 1999; 57: 332-41.
5. Leof EB, Wharton W, van Wyk JJ, Pledger WJ,. Epidermal growth factor (EGF) and somatomedin C regulate G1 progression in competent BALB/c-3T3 cells. Exp Cell Res 1982; 141: 107-15.
6. Sell C, Dumenil G, Deveaud C, Miura M, Coppola D, DeAngelis T, Rubin R, Efstratiadis A, Baserga R,. Effect of a null mutation of the insulin-like growth factor I receptor gene on growth and transformation of mouse embryo fibroblasts. Mol Cell Biol 1994; 14: 3604-12.
7. Sell C, Rubini M, Rubin R, Liu JP, Efstratiadis A, Baserga R,. Simian virus 40 large tumor antigen is unable to transform mouse embryonic fibroblasts lacking type 1 insulin-like growth factor receptor. Proc Natl Acad Sci USA 1993; 90: 11217-21.
8. Sell C, Baserga R, Rubin R,. Insulin-like growth factor I (IGF-I) and the IGF-I receptor prevent etoposide-induced apoptosis. Cancer Res 1995; 55: 303-6.
9. D'Ambrosio C, Ferber A, Resnicoff M, Baserga R,. A soluble insulin-like growth factor I receptor that induces apoptosis of tumor cells in vivo and inhibits tumorigenesis. Cancer Res 1996; 56: 4013-20.
10. Roddam AW, Allen NE, Appleby P, Key TJ, Ferrucci L, Carter HB, Metter EJ, Chen C, Weiss NS, Fitzpatrick A, Hsing AW, Lacey JV, Jr, et al. Insulin-like growth factors, their binding proteins, and prostate cancer risk: analysis of individual patient data from 12 prospective studies. Ann Intern Med 2008; 149: 461-71, W83-8.
11. Key TJ, Appleby PN, Reeves GK, Roddam AW,. Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studies. Lancet Oncol 2010; 11: 530-42.
12. Rinaldi S, Cleveland R, Norat T, Biessy C, Rohrmann S, Linseisen J, Boeing H, Pischon T, Panico S, Agnoli C, Palli D, Tumino R, et al. Serum levels of IGF-I, IGFBP-3 and colorectal cancer risk: results from the EPIC cohort, plus a meta-analysis of prospective studies. Int J Cancer 2010; 126: 1702-15.
13. Chen W, Wang S, Tian T, Bai J, Hu Z, Xu Y, Dong J, Chen F, Wang X, Shen H,. Phenotypes and genotypes of insulin-like growth factor 1, IGF-binding protein-3 and cancer risk: evidence from 96 studies. Eur J Hum Genet 2009; 17: 1668-75.
14. Jemal A, Siegel R, Xu J, Ward E,. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
15. Giovannucci E, Pollak MN, Platz EA, Willett WC, Stampfer MJ, Majeed N, Colditz GA, Speizer FE, Hankinson SE,. A prospective study of plasma insulin-like growth factor-1 and binding protein-3 and risk of colorectal neoplasia in women. Cancer Epidemiol Biomarkers Prev 2000; 9: 345-9.
16. Keku TO, Lund PK, Galanko J, Simmons JG, Woosley JT, Sandler RS,. Insulin resistance, apoptosis, and colorectal adenoma risk. Cancer Epidemiol Biomarkers Prev 2005; 14: 2076-81.
17. Le Marchand L, Wang H, Rinaldi S, Kaaks R, Vogt TM, Yokochi L, Decker R,. Associations of plasma C-peptide and IGFBP-1 levels with risk of colorectal adenoma in a multiethnic population. Cancer Epidemiol Biomarkers Prev 2010; 19: 1471-7.
18. Renehan AG, Painter JE, Atkin WS, Potten CS, Shalet SM, O'Dwyer ST,. High-risk colorectal adenomas and serum insulin-like growth factors. Br J Surg 2001; 88: 107-13.
19. Renehan AG, Painter JE, O'Halloran D, Atkin WS, Potten CS, O'Dwyer ST, Shalet SM,. Circulating insulin-like growth factor II and colorectal adenomas. J Clin Endocrinol Metab 2000; 85: 3402-8.
20. Schoen RE, Weissfeld JL, Kuller LH, Thaete FL, Evans RW, Hayes RB, Rosen CJ,. Insulin-like growth factor-I and insulin are associated with the presence and advancement of adenomatous polyps. Gastroenterology 2005; 129: 464-75.
21. Teramukai S, Rohan T, Lee KY, Eguchi H, Oda T, Kono S,. Insulin-like growth factor (IGF)-I, IGF-binding protein-3 and colorectal adenomas in Japanese men. Jpn J Cancer Res 2002; 93: 1187-94.
22. Hayes RB, Sigurdson A, Moore L, Peters U, Huang WY, Pinsky P, Reding D, Gelmann EP, Rothman N, Pfeiffer RM, Hoover RN, Berg CD,. Methods for etiologic and early marker investigations in the PLCO trial. Mutat Res 2005; 592: 147-54.
23. Prorok PC, Andriole GL, Bresalier RS, Buys SS, Chia D, Crawford ED, Fogel R, Gelmann EP, Gilbert F, Hasson MA, Hayes RB, Johnson CC, et al. Design of the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial. Control Clin Trials 2000; 21: 273S-309S.
24. Gery S, Koeffler HP,. Circadian rhythms and cancer. Cell Cycle 2010; 9: 1097-103.
25. Le Marchand L, Wang H, Rinaldi S, Kaaks R, Vogt TM, Yokochi L, Decker R,. Associations of plasma C-peptide and IGFBP-1 levels with risk of colorectal adenoma in a multiethnic population. Cancer Epidemiol Biomarkers Prev 2010; 19: 1471-7.
26. Flood A, Mai V, Pfeiffer R, Kahle L, Rosen CJ, Lanza E, Schatzkin A,. Serum concentrations of insulin-like growth factor and insulin-like growth factor binding protein 3 and recurrent colorectal adenomas. Cancer Epidemiol Biomarkers Prev 2008; 17: 1493-8.
27. Jacobs ET, Martinez ME, Alberts DS, Ashbeck EL, Gapstur SM, Lance P, Thompson PA,. Plasma insulin-like growth factor I is inversely associated with colorectal adenoma recurrence: a novel hypothesis. Cancer Epidemiol Biomarkers Prev 2008; 17: 300-5.
28. Hunt KJ, Toniolo P, Akhmedkhanov A, Lukanova A, Dechaud H, Rinaldi S, Zeleniuch-Jacquotte A, Shore RE, Riboli E, Kaaks R,. Insulin-like growth factor II and colorectal cancer risk in women. Cancer Epidemiol Biomarkers Prev 2002; 11: 901-5.
29. Ma J, Pollak MN, Giovannucci E, Chan JM, Tao Y, Hennekens CH, Stampfer MJ,. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst 1999; 91: 620-5.
30. Morris JK, George LM, Wu T, Wald NJ,. Insulin-like growth factors and cancer: no role in screening. Evidence from the BUPA study and meta-analysis of prospective epidemiological studies. Br J Cancer 2006; 95: 112-7.
31. Suzuki S, Kojima M, Tokudome S, Suzuki K, Ozasa K, Ito Y, Inaba Y, Tajima K, Nakachi K, Watanabe Y, Tamakoshi A,. Insulin-like growth factor (IGF)-I, IGF-II, IGF binding protein-3, and risk of colorectal cancer: a nested case-control study in the Japan Collaborative Cohort study. Asian Pac J Cancer Prev 2009; 10 (Suppl): 45-9.
32. Jones JI, Clemmons DR,. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 1995; 16: 3-34.
33. Ito Y, Koessler T, Ibrahim AE, Rai S, Vowler SL, Abu-Amero S, Silva AL, Maia AT, Huddleston JE, Uribe-Lewis S, Woodfine K, Jagodic M, et al. Somatically acquired hypomethylation of IGF2 in breast and colorectal cancer. Hum Mol Genet 2008; 17: 2633-43.
34. Freier S, Weiss O, Eran M, Flyvbjerg A, Dahan R, Nephesh I, Safra T, Shiloni E, Raz I,. Expression of the insulin-like growth factors and their receptors in adenocarcinoma of the colon. Gut 1999; 44: 704-8.
35. Cui H, Cruz-Correa M, Giardiello FM, Hutcheon DF, Kafonek DR, Brandenburg S, Wu Y, He X, Powe NR, Feinberg AP,. Loss of IGF2 imprinting: a potential marker of colorectal cancer risk. Science 2003; 299: 1753-5.
36. Kaaks R, Toniolo P, Akhmedkhanov A, Lukanova A, Biessy C, Dechaud H, Rinaldi S, Zeleniuch-Jacquotte A, Shore RE, Riboli E,. Serum C-peptide, insulin-like growth factor (IGF)-I, IGF-binding proteins, and colorectal cancer risk in women. J Natl Cancer Inst 2000; 92: 1592-600.
37. Nomura AM, Stemmermann GN, Lee J, Pollak MN,. Serum insulin-like growth factor I and subsequent risk of colorectal cancer among Japanese-American men. Am J Epidemiol 2003; 158: 424-31.
38. Tsilidis KK, Brancati FL, Pollak MN, Rifai N, Clipp SL, Hoffman-Bolton J, Helzlsouer KJ, Platz EA,. Metabolic syndrome components and colorectal adenoma in the CLUE II cohort. Cancer Causes Control 2010; 21: 1-10.
39. Sekharam M, Zhao H, Sun M, Fang Q, Zhang Q, Yuan Z, Dan HC, Boulware D, Cheng JQ, Coppola D,. Insulin-like growth factor 1 receptor enhances invasion and induces resistance to apoptosis of colon cancer cells through the Akt/Bcl-x(L) pathway. Cancer Res 2003; 63: 7708-16.
40. Sekharam M, Nasir A, Kaiser HE, Coppola D,. Insulin-like growth factor 1 receptor activates c-SRC and modifies transformation and motility of colon cancer in vitro. Anticancer Res 2003; 23: 1517-24.
41. Furstenberger G, Senn HJ,. Insulin-like growth factors and cancer. Lancet Oncol 2002; 3: 298-302.
42. Kawai M, Delany AM, Green CB, Adamo ML, Rosen CJ,. Nocturnin suppresses igf1 expression in bone by targeting the 3' untranslated region of igf1 mRNA. Endocrinology 2010; 151: 4861-70.
43. Mazzoccoli G, Vendemiale G, Inglese M, De Cata A, Piepoli A, Pazienza V, Muscarella LA, Tarquini R,. Neuroendocrine axes function in healthy aging: evaluation of predictive and manipulable blood serum indexes. Biomed Pharmacother 2010, Epub.
44. Mazzoccoli G, De Cata A, Greco A, Carughi S, Giuliani F, Tarquini R,. Circadian rhythmicity of lymphocyte subpopulations and relationship with neuro-endocrine system. J Biol Regul Homeost Agents 2010; 24: 341-50.
45. Haus E, Dumitriu L, Nicolau GY, Bologa S, Sackett-Lundeen L,. Circadian rhythms of basic fibroblast growth factor (bFGF), epidermal growth factor (EGF), insulin-like growth factor-1 (IGF-1), insulin-like growth factor binding protein-3 (IGFBP-3), cortisol, and melatonin in women with breast cancer. Chronobiol Int 2001; 18: 709-27.
46. Pinsky PF, Miller A, Kramer BS, Church T, Reding D, Prorok P, Gelmann E, Schoen RE, Buys S, Hayes RB, Berg CD,. Evidence of a healthy volunteer effect in the prostate, lung, colorectal, and ovarian cancer screening trial. Am J Epidemiol 2007; 165: 874-81.